// App-Quantinova.ai

1155 : Real‐World Cost‐Effectiveness Of Elbasvir/ Grazoprevir (EBR/GZR) In Treatment‐Naive (TN) Patients With Chronic Hepatitis C (CHC) Virus Genotype 1 (GT1) In The United States (US)

Researchers

Presenter

  • Shelby L. Corman

Principal Investigators

  • Bruce Bacon

  • Michael P. Curry

  • Douglas T. Dieterich

  • Steven L. Flamm

  • Yiling Jiang

  • Kris V. Kowdley

  • Scott Milligan

  • Chizoba Nwankwo

  • Naoky C. Tsai

  • Zobair M. Younossi

  • Nezam H. Afdhal

Medical Centers

  • Merck & Co., Inc., Kenilworth, NJ

  • Pharmerit International, Bethesda, MD

  • Washington University School of Medicine, St. Louis, MO

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • Liver Center Swedish Medical Center, Seattle, WA

  • Trio Health Analytics, La Jolla, CA

  • Queens Medical Center University of Hawaii, Honolulu, HI

  • Center for Liver Disease, Department of Medicine, Inova Fairfax Hospital, Falls church, Virginia, United States

  • Merck Sharpe & Dohme, Hoddesdon, United Kingdom,

Locations

  • United States

  • United Kingdom

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Hepatitis C

  • Cirrhosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • grazoprevir

  • Elbasvir

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved